Alnylam Pharmaceuticals
ALNY
#626
Rank
โ‚ฌ28.58 B
Marketcap
222,69ย โ‚ฌ
Share price
-1.87%
Change (1 day)
18.53%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): โ‚ฌ69.73 M

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings (TTM) are โ‚ฌ62.3 M. In 2023 the company made an earning of -โ‚ฌ0.29 B an increase over its 2022 earnings that were of -โ‚ฌ0.88 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) โ‚ฌ69.73 M-124.75%
2023 -โ‚ฌ0.29 B-67.84%
2022 -โ‚ฌ0.88 B36.93%
2021 -โ‚ฌ0.64 B-8.04%
2020 -โ‚ฌ0.7 B-15.66%
2019 -โ‚ฌ0.83 B12.23%
2018 -โ‚ฌ0.74 B62.91%
2017 -โ‚ฌ0.46 B17.78%
2016 -โ‚ฌ0.39 B43.44%
2015 -โ‚ฌ0.27 B60.69%
2014 -โ‚ฌ0.17 B98.2%
2013 -โ‚ฌ83.88 M
2011 -โ‚ฌ49.47 M27.48%
2010 -โ‚ฌ38.81 M-10.92%
2009 -โ‚ฌ43.57 M95.77%
2008 -โ‚ฌ22.26 M
2006 -โ‚ฌ35.65 M-9.13%
2005 -โ‚ฌ39.23 M34.74%
2004 -โ‚ฌ29.12 M36.79%
2003 -โ‚ฌ21.29 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚ฌ0.48 B-861.40%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ4.13 B 6,544.07%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ56.14 M-9.88%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ0.23 B-454.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ27.86 M-144.71%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ9.83 B 15,686.04%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚ฌ6.09 B 9,676.31%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ0.74 B 1,097.82%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel